Literature DB >> 11149415

PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma.

H B Salvesen1, N MacDonald, A Ryan, I J Jacobs, E D Lynch, L A Akslen, S Das.   

Abstract

Loss of heterozygosity and mutations in the PTEN (MMAC1) tumor suppressor gene are frequent in endometrial carcinoma. Promoter hypermethylation has recently been identified as an alternative mechanism of tumor suppressor gene inactivation in cancer, but its importance in the PTEN gene in endometrial carcinoma is unknown. The purpose of our study was to assess the frequency of promoter methylation of the PTEN gene and to determine its correlation with clinicopathologic variables in a prospective and population-based series of endometrial carcinomas with complete follow-up. Presence of PTEN promoter methylation was seen in 26 of 138 patients (19%). Methylation was significantly associated with metastatic disease (p = 0.01) and a microsatellite unstable phenotype (p = 0.006). In conclusion, we find that PTEN promoter methylation is relatively frequent in endometrial carcinoma. Its association with metastatic disease and microsatellite instability implicates its importance in the development of this tumor type.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11149415     DOI: 10.1002/1097-0215(20010101)91:1<22::aid-ijc1002>3.0.co;2-s

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  77 in total

1.  Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

Authors:  G B Mills; Y Lu; E C Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Pten, a protean tumor suppressor.

Authors:  G L Mutter
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 3.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

4.  Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis?

Authors:  Yevgeniya J Ioffe; Katherine B Chiappinelli; David G Mutch; Israel Zighelboim; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2011-10-15       Impact factor: 5.482

5.  Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines.

Authors:  Dong-Zhu Ma; Zhen Xu; Yu-Long Liang; Jian-Ming Su; Zeng-Xia Li; Wen Zhang; Li-Ying Wang; Xi-Liang Zha
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

6.  Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis.

Authors:  Maria Escrivà; Sandra Peiró; Nicolás Herranz; Patricia Villagrasa; Natàlia Dave; Bàrbara Montserrat-Sentís; Stephen A Murray; Clara Francí; Thomas Gridley; Ismo Virtanen; Antonio García de Herreros
Journal:  Mol Cell Biol       Date:  2008-01-02       Impact factor: 4.272

7.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 8.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

9.  PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.

Authors:  Xiao-Ping Zhou; Anu Loukola; Reijo Salovaara; Minna Nystrom-Lahti; Päivi Peltomäki; Albert de la Chapelle; Lauri A Aaltonen; Charis Eng
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.

Authors:  Chiaki Banzai; Koji Nishino; Jinhua Quan; Kosuke Yoshihara; Masayuki Sekine; Tetsuro Yahata; Kenichi Tanaka
Journal:  Int J Clin Oncol       Date:  2013-03-14       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.